Company Updates
ISAG – Construction Update
To read the full ASX Announcement please download the document below.
Carnegie awarded UK Wave Hub site for CETO 6
To read the full ASX Announcement please download the document below.
Independent Reserve confirms Banking Partner
Dear Investor, Quite a lot of exciting developments have happened since our last update in January! Here is our news: Last time we mentioned that we have submitted to ASIC the documentation required for an Australian Financial Services Licence (AFSL). Since then, we have been in frequent communication with ASIC regarding what we are doing, […]
$1.9m Government Grant Milestone Payments
To read the full ASX Announcement please download the document below.
NTA features on Switzer
Bridging the working capital and commercial funding gap for SMEs Switzer Daily, Published: Thursday, March 27, 2014 “It is estimated that the commercial lending market is valued at $9 billion per year. However, the SME market is severely underserviced representing under 10% of this figure. Banks that spend millions on capturing new business customers are […]
New institutional investor in Beyond Carbon
To read the full ASX Release please download the document below.
Bridging the working capital and commercial funding gap for SMEs
Source Switzer Daily, by Steve Torso It is estimated that the commercial lending market is valued at $9 billion per year. However, the SME market is severely underserviced representing under 10% of this figure. Banks that spend millions on capturing new business customers are failing existing customers by not approving lending. An East & Partners […]
Cloud DC secures $1M in Funding
Press Release, 27 March 2014, by Steve Robinson, Chief Executive Officer A private consortium has made a cornerstone investment of $1M in Cloud DC, as a part of the current series ‘A’ capital raising exercise. This will provide Cloud DC with working capital to continue on the path of becoming the market leader in Cloud […]
PharmAust bringing a new first-line treatment, PPL1, for tumour cancer patients worldwide
Worldwide cancer accounts for over 10 million deaths per year. In Australia alone, 3 in 10 deaths are due to this cause. Treatments have advanced considerably in the last decade but the majority of therapies are highly toxic, untargeted and inadequate for late stage cancer patients. A new breakthrough drug, PPL1 from PharmAust, offers a […]
Backed By Leading Investment Groups and Family Offices
